StockData

Agenus vs Beam Therapeutics

AGEN and BEAM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and BEAM compare

Beam Therapeutics is the larger company, worth 7.1 times as much as Agenus ($2.2B against $303M).

Beam Therapeutics grew revenue faster over the last twelve months (159% versus 30.5% for Agenus).

Beam Therapeutics scores higher on the StockData Score (9 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENBEAM
Size and price
Market cap$303M$2.2B
Share price$6.73$20.94
Change, 1 year51.9%−3.3%
Change, 5 years−90.4%−73.4%
Beta (5Y)–2.41
Employees81511
StockData Score
Total score39 (better)
Valuation score12 (better)
Growth score22
Performance score03 (better)
Health score02 (better)
Dividend score00
Valuation
P/S2.3× (better)13.9×
P/B–2.0×
EV/EBITDA7.5×–
FCF yield−32.5%−17.2% (better)
Fair value–$23.91
Margin of safety–12.4%
Growth
Revenue growth (TTM)30.5%159% (better)
Revenue growth, 5Y average5.3%466% (better)
Profitability
Gross margin99.5%–
Operating margin27.3% (better)−242%
Net margin–−54.7%
FCF margin−74.2% (better)−239%
Return on equity–−8.1%
Financial health
Debt / equity–0.09
Net debt / EBITDA0.28–
Interest coverage0.6×–
Current ratio0.3414.57 (better)
Altman Z-score−16.502.36 (better)
Piotroski F-score–4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions31.7%106%
Held by insiders6.6%3.4%
Insider net buying, 12 months–−$19.7M
Superinvestors holding–1
Short interest, % of float18.1%26.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.